Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids

• Published in: Toxicological sciences Vol. 176; no. 2; pp. 460 - 469
• Main Authors: Mallick, Pankajini, Song, Gina, Efremenko, Alina Y, Pendse, Salil N, Creek, Moire R, Osimitz, Thomas G, Hines, Ronald N, Hinderliter, Paul, Clewell, Harvey J, Lake, Brian G, Yoon, Miyoung, Moreau, Marjory
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 01.08.2020
• Subjects: Regulatory Science, Risk Assessment, and Decision Making; pyrethroids; risk assessment; PBPK modeling; IVIVE
• ISSN: 1096-6080; 1096-0929
• DOI: 10.1093/toxsci/kfaa070

Abstract The assessment of potentially sensitive populations is an important application of risk assessment. To address the concern for age-related sensitivity to pyrethroid insecticides, life-stage physiologically based pharmacokinetic (PBPK) modeling supported by in vitro to in vivo extrapolation was conducted to predict age-dependent changes in target tissue exposure to 8 pyrethroids. The purpose of this age-dependent dosimetry was to calculate a Data-derived Extrapolation Factor (DDEF) to address age-related pharmacokinetic differences for pyrethroids in humans. We developed a generic human PBPK model for pyrethroids based on our previously published rat model that was developed with in vivo rat data. The results demonstrated that the age-related differences in internal exposure to pyrethroids in the brain are largely determined by the differences in metabolic capacity and in physiology for pyrethroids between children and adults. The most important conclusion from our research is that, given an identical external exposure, the internal (target tissue) concentration is equal or lower in children than in adults in response to the same level of exposure to a pyrethroid. Our results show that, based on the use of the life-stage PBPK models with 8 pyrethroids, DDEF values are essentially close to 1, resulting in a DDEF for age-related pharmacokinetic differences of 1. For risk assessment purposes, this indicates that no additional adjustment factor is necessary to account for age-related pharmacokinetic differences for these pyrethroids.